Interleukin-21 Activates Cytotoxic T Lymphocytes and Natural Killer Cells to Generate Antitumor Response in Mouse Renal Cell Carcinoma

Journal of Urology

Volumn 178, Issue 4, 2007, Pages 1504-1509

  Kumano, Masafumi ^a   Hara, Isao ^a   Furukawa, Junya ^a   Oniki, Shuntaro ^a   Nagai, Hiroshi ^a   Miyake, Hideaki ^a   Fujisawa, Masato ^a  

^a KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

gene therapy; interleukin 21; kidney; mice; renal cell carcinoma

Indexed keywords

INTERLEUKIN 21; LIPOSOME; MITOMYCIN C; TUMOR VACCINE;

ADOLESCENT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BAGG ALBINO MOUSE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL GROWTH; CYTOKINE RELEASE; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; GENE THERAPY; IMMUNOHISTOCHEMISTRY; KIDNEY CARCINOMA; LYMPHOCYTE ACTIVATION; MOUSE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; SPLEEN CELL; T LYMPHOCYTE ACTIVATION;

ANIMALS; CANCER VACCINES; CARCINOMA, RENAL CELL; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; CYTOTOXICITY TESTS, IMMUNOLOGIC; FEMALE; GENE TRANSFER TECHNIQUES; INTERLEUKINS; KIDNEY NEOPLASMS; KILLER CELLS, NATURAL; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED BALB C; NEOPLASM TRANSPLANTATION; T-LYMPHOCYTES, CYTOTOXIC; TRANSDUCTION, GENETIC;

EID: 34548422381     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.juro.2007.05.115     Document Type: Article

References (14)

1. McDermott D.F., Regan M.M., Clark J.I., Flaherty L.E., Weiss G.R., Logan T.F., et al. Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J Clin Oncol 23 (2005) 133
2. Tagawa M. Cytokine therapy for cancer. Curr Pharmacol Des 6 (2000) 681
3. Abbas A.K., Murphy K.M., and Sher A. Functional diversity of helper T lymphocytes. Nature 383 (1996) 787
4. Hara I., Nguyen H., Takechi Y., Gansbacher B., Chapman P.B., and Houghton A.N. Rejection of mouse melanoma elicited by local secretion of interleukin-2: implicating macrophages without T cells or natural killer cells in tumor rejection. Int J Cancer Res 61 (1995) 253
5. Hara I., Nagai H., Miyake H., Yamanaka K., Hara S., Micallef M.J., et al. Effectiveness of cancer vaccine therapy using cells transduced with the interleukin-12 gene combined with systemic interleukin-18 administration. Cancer Gene Ther 7 (2000) 83
6. Leonard W.J., and Spolski R. Interleukin-21: a modulator of lymphoid proliferation, apoptosis and differentiation. Nat Rev Immunol 5 (2005) 688
7. Furukawa J., Hara I., Nagai H., Yao A., Oniki S., and Fujisawa M. Interleukin-21 gene transfection into mouse bladder cancer cells results in tumor rejection through the cytotoxic T lymphocyte response. J Urol 176 (2006) 1198
8. Zeng R., Spolski R., Finkelstein S.E., Oh S., Kovanen P.E., Hinrichs C.S., et al. Synergy of IL-21 and IL-15 in regulating CD8+ T cell expansion and function. J Exp Med 201 (2005) 139
9. Curti B.D. Immunomodulatory and antitumor effects of interleukin-21 in patients with renal cell carcinoma. Expert Rev Anticancer Ther 6 (2006) 905
10. Brady J., Hayakawa Y., Smyth M.J., and Nutt S.L. IL-21 induces the functional maturation of murine NK cells. J Immunol 172 (2004) 2048
11. Motzer R.J., Michaelson M.D., Redman B.G., Hudes G.R., Wilding G., Figlin R.A., et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 24 (2006) 16
12. Ugai S., Shimozato O., Kawamura K., Wang Y.Q., Yamaguchi T., Saisho H., et al. Expression of the interleukin-21 gene in murine colon carcinoma cells generates systemic immunity in the inoculated hosts. Cancer Gene Ther 10 (2003) 187
13. Ma H.L., Whitters M.J., Konz R.F., Senices M., Young D.A., Grusby M.J., et al. IL-21 activates both innate and adaptive immunity to generate potent antitumor responses that require perforin but are independent of IFN-gamma. J Immunol 171 (2003) 608
14. DiCarlo E., Comes A., Orengo A.M., Rosso O., Meazza R., Musiani P., et al. IL-21 induces tumor rejection by specific CTL and IFN-gamma-dependent CXC chemokines in syngeneic mice. J Immunol 172 (2004) 1540